JP5713917B2 - 抗フェロポーチン１モノクローナル抗体およびその使用 - Google Patents

抗フェロポーチン１モノクローナル抗体およびその使用 Download PDF

Info

Publication number
JP5713917B2
JP5713917B2 JP2011539625A JP2011539625A JP5713917B2 JP 5713917 B2 JP5713917 B2 JP 5713917B2 JP 2011539625 A JP2011539625 A JP 2011539625A JP 2011539625 A JP2011539625 A JP 2011539625A JP 5713917 B2 JP5713917 B2 JP 5713917B2
Authority
JP
Japan
Prior art keywords
seq
mab
fpn1
amino acid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011539625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510814A (ja
JP2012510814A5 (enExample
Inventor
ドンミエン・ドーン・マン・レウン
ペン・ルアン
ジョゼフ・ビンセント・マネッタ
タン・イン
デリック・ライアン・ウィッチャー
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2012510814A publication Critical patent/JP2012510814A/ja
Publication of JP2012510814A5 publication Critical patent/JP2012510814A5/ja
Application granted granted Critical
Publication of JP5713917B2 publication Critical patent/JP5713917B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011539625A 2008-12-05 2009-12-01 抗フェロポーチン１モノクローナル抗体およびその使用 Expired - Fee Related JP5713917B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US61/120,076 2008-12-05
US23981809P 2009-09-04 2009-09-04
US61/239,818 2009-09-04
PCT/US2009/066187 WO2010065496A1 (en) 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2012510814A JP2012510814A (ja) 2012-05-17
JP2012510814A5 JP2012510814A5 (enExample) 2013-01-24
JP5713917B2 true JP5713917B2 (ja) 2015-05-07

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011539625A Expired - Fee Related JP5713917B2 (ja) 2008-12-05 2009-12-01 抗フェロポーチン１モノクローナル抗体およびその使用

Country Status (25)

Country Link
EP (1) EP2373335B1 (enExample)
JP (1) JP5713917B2 (enExample)
KR (1) KR101353117B1 (enExample)
CN (1) CN102238962B (enExample)
AR (1) AR074398A1 (enExample)
AU (1) AU2009322587B2 (enExample)
BR (1) BRPI0922288A2 (enExample)
CA (1) CA2745618C (enExample)
CY (1) CY1117355T1 (enExample)
DK (1) DK2373335T3 (enExample)
EA (1) EA020472B1 (enExample)
ES (1) ES2566343T3 (enExample)
HR (1) HRP20160302T1 (enExample)
HU (1) HUE028585T2 (enExample)
IL (1) IL212731A0 (enExample)
MX (1) MX2011005939A (enExample)
NZ (1) NZ592545A (enExample)
PA (1) PA8849601A1 (enExample)
PL (1) PL2373335T3 (enExample)
SG (1) SG171960A1 (enExample)
SI (1) SI2373335T1 (enExample)
TW (1) TW201023891A (enExample)
UA (1) UA104741C2 (enExample)
WO (1) WO2010065496A1 (enExample)
ZA (1) ZA201103941B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027905A2 (pt) * 2012-05-14 2017-06-27 Genentech Inc anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
WO2019213016A1 (en) 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
EP2803675A3 (en) * 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use

Also Published As

Publication number Publication date
WO2010065496A1 (en) 2010-06-10
AR074398A1 (es) 2011-01-12
JP2012510814A (ja) 2012-05-17
CA2745618C (en) 2014-06-10
CA2745618A1 (en) 2010-06-10
AU2009322587A1 (en) 2011-07-28
EA201170764A1 (ru) 2011-12-30
HUE028585T2 (en) 2016-12-28
HK1158977A1 (zh) 2012-07-27
KR20110084996A (ko) 2011-07-26
UA104741C2 (uk) 2014-03-11
AU2009322587B2 (en) 2013-09-26
CN102238962A (zh) 2011-11-09
SG171960A1 (en) 2011-07-28
KR101353117B1 (ko) 2014-02-17
EP2373335A1 (en) 2011-10-12
MX2011005939A (es) 2011-06-27
IL212731A0 (en) 2011-07-31
TW201023891A (en) 2010-07-01
PL2373335T3 (pl) 2016-08-31
SI2373335T1 (sl) 2016-04-29
HRP20160302T1 (hr) 2016-04-22
NZ592545A (en) 2012-12-21
EA020472B1 (ru) 2014-11-28
ES2566343T3 (es) 2016-04-12
BRPI0922288A2 (pt) 2018-08-28
DK2373335T3 (en) 2016-05-02
CN102238962B (zh) 2014-02-12
ZA201103941B (en) 2012-11-28
PA8849601A1 (es) 2010-07-27
EP2373335B1 (en) 2016-02-24
CY1117355T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
US8183346B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP6598958B2 (ja) 抗ヘプシジン抗体およびその使用
US20210403558A1 (en) Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
KR102453227B1 (ko) 항-axl 길항성 항체
KR102458196B1 (ko) 항-axl 길항성 항체
KR102366853B1 (ko) Cd47 항체 및 사이토카인을 포함하는 융합 단백질
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
CN103068848A (zh) 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
JP2025148445A (ja) 抗ｎｐｒ１抗体およびその使用
US10894833B2 (en) Agents, uses and methods for treatment
KR101353117B1 (ko) 항-페로포틴 １ 모노클로날 항체 및 이의 용도
JP2022169737A (ja) 抗ｒａｍｐ２抗体
AU2022210475A1 (en) Anti-PDGF-B antibodies and methods of use for treating pulmonary arterial hypertension (PAH)
CN116887859A (zh) Ccr6抗体
HK1158977B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP2025523477A (ja) インテグリンアルファ１１ベータ１に対する抗体及びその使用
HK1220379B (en) Anti-hepcidin antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150310

R150 Certificate of patent or registration of utility model

Ref document number: 5713917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees